Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

Area of Science:

• Molecular Biology
• Oncology
• Epigenetics

Background:

• Epigenetic regulation is increasingly recognized for its role in tumor development and prognosis.
• Abnormal histone acetylation is a hallmark of cancer, indicating its significance in tumorigenesis.
• Targeting epigenetic mechanisms represents a promising strategy for novel cancer therapeutics.

Purpose of the Study:

• To review the alterations in histone acetylation levels during cancer development.
• To summarize the pharmacological mechanisms of small molecules targeting histone acetylation for cancer treatment.
• To highlight the potential of targeting histone acetylation regulatory enzymes and proteins in oncology.

Main Methods:

• Review of recent scientific literature on epigenetic regulation in cancer.
• Analysis of studies focusing on small molecules targeting histone acetylation.
• Examination of enzymes and proteins involved in histone acetylation, including HDACs, HATs, and BRDs.

Main Results:

• Significant changes in histone acetylation patterns are observed during tumorigenesis.
• Development of various small molecules targeting key regulators of histone acetylation.
• These molecules aim to normalize aberrant histone acetylation levels in cancer cells.

Conclusions:

• Targeting histone acetylation is a viable strategy for developing new anti-cancer drugs.
• Small molecules modulating histone acetylation offer potential therapeutic benefits in cancer treatment.
• Further research into these epigenetic modulators could lead to improved cancer therapies.